ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Atlanta, GA, USA:

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT)

Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatme ...

Enrolling
Triple Negative Breast Cancer
Drug: Merck 3475 Pembrolizumab
Radiation: Intraoperative radiation therapy (IORT)

Phase 1

Eileen Connolly

Atlanta, Georgia, United States and 2 other locations

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple...

Enrolling
Triple Negative Breast Cancer
Drug: ProAgio Dose Levels (DL) 1,2,3,4
Drug: ProAgio Dose Expansion

Phase 1, Phase 2

ProDa BioTech

Atlanta, Georgia, United States and 1 other location

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Atlanta, Georgia, United States and 49 other locations

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Atezolizumab
Drug: Placebo

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Duluth, Georgia, United States and 216 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Atlanta, Georgia, United States and 165 other locations

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is th...

Enrolling
Hormone Receptor Positive Breast Cancer
Non-small Cell Lung Cancer
Drug: Steroid Containing Mouthwash
Other: Non-Steroid Containing Mouthwash

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Atlanta, Georgia, United States and 17 other locations

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 228 other locations

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Atlanta, Georgia, United States and 516 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Atlanta, Georgia, United States and 505 other locations

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 360 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems